Simon Cheong1, Shuting Sun2, Benjamin Kang3, Olga Bezouglaia4, David Elashoff5, Charles E McKenna6, Tara L Aghaloo7, Sotirios Tetradis8. 1. Dental Student, University of Southern California, Herman Ostrow School of Dentistry, Los Angeles, CA. 2. Research Associate, Department of Chemistry, University of Southern California, Los Angeles, CA. 3. Dental Student, University of Michigan School of Dentistry, Ann Arbor, MI. 4. Research Associate, Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA. 5. Professor, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA. 6. Professor, Department of Chemistry, University of Southern California, Los Angeles, CA. 7. Associate Professor, Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles, CA. 8. Professor, Division of Diagnostic and Surgical Sciences, UCLA School of Dentistry, Los Angeles; Molecular Biology Institute, UCLA, Los Angeles, CA. Electronic address: taghaloo@dentistry.ucla.edu.
Abstract
PURPOSE: Bisphosphonates (BPs) are widely used for the management of bone diseases such as osteoporosis and bone malignancy. However, osteonecrosis of the jaws (ONJ) is a serious complication of BP treatment. ONJ lesions mainly occur after extraction of teeth deemed unrestorable or around teeth with active periodontal or periapical disease. Because socket healing or dental disease shows higher bone turnover, the authors hypothesized that preferentially high BP accumulation would be observed in these areas. MATERIALS AND METHODS: The authors tested the uptake of fluorescein-labeled zoledronic acid (5-FAM-ZOL) in sites of tooth extraction or experimental periapical disease in mice. Maxillary molars were extracted or the crowns of mandibular molars were drilled to induce pulp exposure. Animals were injected with 5-FAM-ZOL 200 μg/kg at various times after intervention and fluorescence was measured at healthy versus intervention sites. Fluorescein injections were used as controls. Data were analyzed by t test and mixed effects linear models were constructed because the animals had repeated measurements over time and at the 2 sites. RESULTS: A statistically significant (P≤.001 to .002) time-dependent uptake of 5-FAM-ZOL was detected in the areas of extraction socket and in the alveolar ridge around teeth with periapical disease compared with the healthy contralateral sites of the same animals. For the 2 conditions, the uptake reached a maximum 3 days after experimental intervention and decreased thereafter. CONCLUSIONS: These data suggest that sites with increased bone turnover, such as extraction sites or areas of periapical inflammation, are exposed to higher BP doses than the remaining alveolar ridge and could explain, at least in part, the susceptibility of such areas to ONJ.
PURPOSE:Bisphosphonates (BPs) are widely used for the management of bone diseases such as osteoporosis and bone malignancy. However, osteonecrosis of the jaws (ONJ) is a serious complication of BP treatment. ONJ lesions mainly occur after extraction of teeth deemed unrestorable or around teeth with active periodontal or periapical disease. Because socket healing or dental disease shows higher bone turnover, the authors hypothesized that preferentially high BP accumulation would be observed in these areas. MATERIALS AND METHODS: The authors tested the uptake of fluorescein-labeled zoledronic acid (5-FAM-ZOL) in sites of tooth extraction or experimental periapical disease in mice. Maxillary molars were extracted or the crowns of mandibular molars were drilled to induce pulp exposure. Animals were injected with 5-FAM-ZOL 200 μg/kg at various times after intervention and fluorescence was measured at healthy versus intervention sites. Fluorescein injections were used as controls. Data were analyzed by t test and mixed effects linear models were constructed because the animals had repeated measurements over time and at the 2 sites. RESULTS: A statistically significant (P≤.001 to .002) time-dependent uptake of 5-FAM-ZOL was detected in the areas of extraction socket and in the alveolar ridge around teeth with periapical disease compared with the healthy contralateral sites of the same animals. For the 2 conditions, the uptake reached a maximum 3 days after experimental intervention and decreased thereafter. CONCLUSIONS: These data suggest that sites with increased bone turnover, such as extraction sites or areas of periapical inflammation, are exposed to higher BP doses than the remaining alveolar ridge and could explain, at least in part, the susceptibility of such areas to ONJ.
Authors: Shuting Sun; Katarzyna M Błażewska; Boris A Kashemirov; Anke J Roelofs; Fraser P Coxon; Michael J Rogers; Frank H Ebetino; Michael J McKenna; Charles E McKenna Journal: Phosphorus Sulfur Silicon Relat Elem Date: 2011-04
Authors: Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis Journal: J Bone Miner Res Date: 2013-07 Impact factor: 6.741
Authors: Jenny A F Vermeer; Ineke D C Jansen; Matangi Marthi; Fraser P Coxon; Charles E McKenna; Shuting Sun; Teun J de Vries; Vincent Everts Journal: Bone Date: 2013-08-17 Impact factor: 4.398
Authors: Sundeep Khosla; David Burr; Jane Cauley; David W Dempster; Peter R Ebeling; Dieter Felsenberg; Robert F Gagel; Vincente Gilsanz; Theresa Guise; Sreenivas Koka; Laurie K McCauley; Joan McGowan; Marc D McKee; Suresh Mohla; David G Pendrys; Lawrence G Raisz; Salvatore L Ruggiero; David M Shafer; Lillian Shum; Stuart L Silverman; Catherine H Van Poznak; Nelson Watts; Sook-Bin Woo; Elizabeth Shane Journal: J Bone Miner Res Date: 2007-10 Impact factor: 6.741
Authors: Anke J Roelofs; Fraser P Coxon; Frank H Ebetino; Mark W Lundy; Zachary J Henneman; George H Nancollas; Shuting Sun; Katarzyna M Blazewska; Joy Lynn F Bala; Boris A Kashemirov; Aysha B Khalid; Charles E McKenna; Michael J Rogers Journal: J Bone Miner Res Date: 2010-03 Impact factor: 6.741
Authors: Parish P Sedghizadeh; Shuting Sun; Adam F Junka; Eric Richard; Keivan Sadrerafi; Susan Mahabady; Neema Bakhshalian; Natalia Tjokro; Marzenna Bartoszewicz; Monika Oleksy; Patrycja Szymczyk; Mark W Lundy; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino Journal: J Med Chem Date: 2017-02-13 Impact factor: 7.446
Authors: Rafael Scaf de Molon; Chingyun Hsu; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Akrivoula Soundia; Fernando Queiroz Cunha; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis Journal: J Bone Miner Res Date: 2016-05-04 Impact factor: 6.741
Authors: Tarek Metwally; Andrea Burke; Jeffrey Y Tsai; Michael T Collins; Alison M Boyce Journal: J Oral Maxillofac Surg Date: 2016-04-07 Impact factor: 1.895
Authors: Shuting Sun; Katarzyna M Błażewska; Anastasia P Kadina; Boris A Kashemirov; Xuchen Duan; James T Triffitt; James E Dunford; R Graham G Russell; Frank H Ebetino; Anke J Roelofs; Fraser P Coxon; Mark W Lundy; Charles E McKenna Journal: Bioconjug Chem Date: 2015-12-08 Impact factor: 4.774
Authors: Parish P Sedghizadeh; Shuting Sun; Allan C Jones; Esmat Sodagar; Philip Cherian; Casey Chen; Adam F Junka; Jeffrey D Neighbors; Charles E McKenna; R Graham G Russell; Frank H Ebetino Journal: Bone Date: 2021-03-20 Impact factor: 4.626
Authors: Shuting Sun; Jianguo Tao; Parish P Sedghizadeh; Philip Cherian; Adam F Junka; Esmat Sodagar; Lianping Xing; Robert K Boeckman; Venkatesan Srinivasan; Zhenqiang Yao; Brendan F Boyce; Brea Lipe; Jeffrey D Neighbors; R Graham G Russell; Charles E McKenna; Frank H Ebetino Journal: Br J Pharmacol Date: 2021-04-10 Impact factor: 8.739